Gilead Sciences (GILD) Non-Current Assets (2009 - 2026)

Gilead Sciences (GILD) posted Non-Current Assets of $37.6 billion for Q1 2026, down 7.48% quarter-over-quarter from $40.7 billion in Q4 2025, and down 4.8% year-on-year from $39.5 billion in Q1 2025.

Gilead Sciences (GILD) Non-Current Assets (2009 - 2026) Analysis & Trends

Gilead Sciences (GILD) has reported Non-Current Assets for 18 consecutive years, with $37.6 billion the latest figure, recorded in Q1 2026.

  • Non-Current Assets for Q1 2026 came in at $37.6 billion, down 4.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $160.0 billion (changed 0.24% YoY), and the FY2025 annual result was $40.7 billion, up 2.16% from the prior year.
  • Non-Current Assets was $37.6 billion for Q1 2026 at Gilead Sciences, down from $40.7 billion in the prior quarter.
  • Over five years, Non-Current Assets peaked at $50.5 billion in Q1 2022 and troughed at $37.6 billion in Q1 2026.
  • Average Non-Current Assets over 5 years is $44.1 billion, with a median of $42.3 billion recorded in 2024.
  • Year-over-year, Non-Current Assets slipped 14.33% in 2024 and climbed 2.3% in 2025.
  • Over 5 years, Non-Current Assets stood at $48.7 billion in 2022, then decreased by 5.52% to $46.0 billion in 2023, then decreased by 13.51% to $39.8 billion in 2024, then gained by 2.16% to $40.7 billion in 2025, then fell by 7.48% to $37.6 billion in 2026.
  • Per Business Quant data, the three most recent Non-Current Assets figures were $37.6 billion in Q1 2026, $40.7 billion in Q4 2025, and $40.7 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 61.74 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 141.72 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 102.93 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 84.40 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 125.00 Mn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 61.03 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 37.64 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 165.18 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn 20.29 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 37.64 Bn
Dec 31, 2025 40.68 Bn
Sep 30, 2025 40.66 Bn
Jun 30, 2025 41.00 Bn
Mar 31, 2025 39.53 Bn
Dec 31, 2024 39.82 Bn
Sep 30, 2024 39.75 Bn
Jun 30, 2024 41.26 Bn
Mar 31, 2024 42.25 Bn
Dec 31, 2023 46.04 Bn
Sep 30, 2023 46.39 Bn
Jun 30, 2023 48.05 Bn
Mar 31, 2023 48.42 Bn
Dec 31, 2022 48.73 Bn
Sep 30, 2022 49.00 Bn
Jun 30, 2022 49.70 Bn
Mar 31, 2022 50.45 Bn
Dec 31, 2021 53.18 Bn
Sep 30, 2021 53.11 Bn
Jun 30, 2021 54.06 Bn